Hopes of developing a Zika vaccine took a small step forward on Wednesday as Inovio Pharmaceuticals Inc (INO.O) said its experimental shot had induced a robust and durable response in mice.
Shares in the U.S. biotech firm, which expects to test its product in humans before the end of the year, jumped 7 percent in premarket trading on the prospect of it developing a vaccine against the mosquito-borne disease.
At least 15 companies and academic groups are currently racing to develop Zika vaccines, according . . .
Already a Subscriber? Login Here
